CRISPR Therapeutics AG Common Shares (CRSP)

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Website

crisprtx.com/

Fundamentals

1-day range

$57.1$59.37

Market cap

$4.78B

P/E (trailing)

—

P/E (forward)

-16.50

EPS (trailing)

$-4.76

Dividend yield

—

Beta

1.79

Avg. volume

1.65M

Forecasts

18 analyst ratings

CRISPR Therapeutics AG Common Shares Competitors

Chosen by industry and closest market cap.

• CRSP

  CRISPR Therapeutics AG Common Shares

  $57.69

  ▼ 2.84%
  Market cap $4.78BP/E —
  $44.12$78.48
• ADPT

  Adaptive Biotechnologies Corporation Common Stock

  $25.19

  ▼ 4.73%
  Market cap $3.70BP/E —
  $12$26.87
• RLAY

  Relay Therapeutics Inc. Common Stock

  $18.78

  ▼ 3.30%
  Market cap $3.60BP/E —
  $3.5$21.27
• BEAM

  Beam Therapeutics Inc. Common Stock

  $29.31

  ▼ 3.84%
  Market cap $2.67BP/E —
  $16.02$38.26
• KOD

  Kodiak Sciences Inc Common Stock

  $37.77

  ▼ 3.45%
  Market cap $2.49BP/E —
  $8.29$47.84
• COAG

  Hemab Therapeutics Holdings Inc. Common Stock

  $44.77

  ▼ 9.55%
  Market cap $2.10BP/E —
  $23$55.42
• MESO

  Mesoblast Limited American Depositary Shares

  $17.42

  ▼ 4.18%
  Market cap $1.87BP/E —
  $1.88$3.31

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• CRISPR Therapeutics Data From Its Phase 1 Clinical Study Of CTX Shows 79% Mean Reductions From Baseline For ANGPTL3, 48% Maximum For Triglycerides
  Benzinga · 8/28/2026
• Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target
  Benzinga · 8/25/2026
• Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
  benzinga · 8/20/2026
• Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
  Benzinga · 8/20/2026
• Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
  Benzinga · 8/19/2026
• Tracking Cathie Wood's ARK Invest 13F Portfolio - Q2 2026 Update
  SeekingAlpha · 8/19/2026
• Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
  Benzinga · 8/19/2026
• Prime Medicine: An Initial Prognosis
  SeekingAlpha · 8/11/2026
• CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310
  SeekingAlpha · 8/5/2026

• Raju Prasad · August 7, 2026 · Gift

  750
• Fleming Harold Edward · June 5, 2026 · Grant

  13.0K
• Rommel Christian · June 5, 2026 · Grant

  13.0K
• Treco Douglas A · June 5, 2026 · Grant

  13.0K
• Morrison Briggs · June 5, 2026 · Grant

  13.0K
• Katherine A. High · June 5, 2026 · Grant

  13.0K
• Ali Behbahani · June 5, 2026 · Grant

  13.0K
• Greene John · June 5, 2026 · Grant

  13.0K
• George Simeon · June 5, 2026 · Grant

  13.0K
• Fardis Maria · June 5, 2026 · Grant

  13.0K
• Mahatme Sandesh · June 5, 2026 · Grant

  13.0K
• James R. Kasinger · May 29, 2026 · Grant

  17.0K
• Naimish Patel · May 29, 2026 · Grant

  22.0K
• Raju Prasad · May 29, 2026 · Grant

  19.5K
• Naimish Patel · May 29, 2026 · Sale

  3.8K @ $55.62